The Brokerages Set Acceleron Pharma Inc. (XLRN) PT at $44.50

The Brokerages Set Acceleron Pharma Inc. (XLRN) PT at $44.50

Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) have received a consensus recommendation of “Buy” from the eleven analysts that are covering the firm. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $44.50.

A number of analysts have weighed in on XLRN shares. Morgan Stanley reissued an “overweight” rating on shares of Acceleron Pharma in a research report on Wednesday, June 29th. Credit Suisse Group AG reissued a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, July 10th. Zacks Investment Research raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Wednesday, July 20th. FBR & Co reissued a “buy” rating and set a $63.00 target price on shares of Acceleron Pharma in a research report on Friday, August 5th. Finally, BTIG Research started coverage on shares of Acceleron Pharma in a research report on Friday, August 19th. They set a “buy” rating and a $46.00 target price for the company.

In related news, SVP John D. Quisel sold 21,438 shares of the stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $32.14, for a total transaction of $689,017.32. Following the completion of the sale, the senior vice president now owns 86,723 shares in the company, valued at $2,787,277.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP John D. Quisel sold 45,952 shares of the stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $38.05, for a total value of $1,748,473.60. Following the sale, the senior vice president now owns 77,004 shares of the company’s stock, valued at approximately $2,930,002.20. The disclosure for this sale can be found here. 12.20% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC boosted its stake in Acceleron Pharma by 1.0% in the second quarter. Parametric Portfolio Associates LLC now owns 8,797 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 90 shares in the last quarter. Legal & General Group Plc boosted its stake in Acceleron Pharma by 4.3% in the second quarter. Legal & General Group Plc now owns 4,214 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 173 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Acceleron Pharma by 1.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 18,078 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 185 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in Acceleron Pharma by 0.6% in the second quarter. Mutual of America Capital Management LLC now owns 44,663 shares of the biopharmaceutical company’s stock valued at $1,518,000 after buying an additional 250 shares in the last quarter. Finally, Tocqueville Asset Management L.P. boosted its stake in Acceleron Pharma by 2.2% in the second quarter. Tocqueville Asset Management L.P. now owns 19,750 shares of the biopharmaceutical company’s stock valued at $671,000 after buying an additional 425 shares in the last quarter. Hedge funds and other institutional investors own 75.55% of the company’s stock.

Shares of Acceleron Pharma (NASDAQ:XLRN) opened at 30.34 on Tuesday. The stock has a 50 day moving average of $34.14 and a 200-day moving average of $32.67. The company’s market cap is $1.14 billion. Acceleron Pharma has a 12 month low of $22.67 and a 12 month high of $50.86.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by $0.09. The firm had revenue of $3.20 million for the quarter, compared to analyst estimates of $3.77 million. Acceleron Pharma had a negative net margin of 190.41% and a negative return on equity of 30.00%. Acceleron Pharma’s revenue was down 43.9% on a year-over-year basis. On average, analysts forecast that Acceleron Pharma will post ($1.59) EPS for the current year.

Related posts

Leave a Comment